SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Schweiger Dermatology group (“SDG”) to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania, and Connecticut. The agreement will provide Schweiger Dermatology Group’s Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.
“We are excited to integrate the Nevisense test during routine skin exams in our Freehold and Verona, New Jersey offices and offer our patients the latest technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and treatment are critical for improving survival rates. Providing our patients with the most advanced technology further supports our commitment to delivering the best care to our patients,” said Dr. Jason H. Miller, Medical Director for New Jersey and Long Island for Schweiger Dermatology Group.
“We are very pleased to announce our collaboration with Schweiger Dermatology Group. In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group’s Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology. For SciBase, we establish a further partner that helps introduce Nevisense to US payers,” said Simon Grant, Chief Executive Officer of SciBase.